雅虎香港 搜尋

搜尋結果

1. www.eisai.com › news › 2024EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN ...

   www.eisai.com › news › 2024

   • 網頁紀錄

   2024年3月29日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant ®

2. www.eisai.com › news › 2022EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL® AND ...

   www.eisai.com › news › 2022

   • 網頁紀錄

   2022年11月7日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment ®

3. www.jcnnewswire.com › english › pressreleaseEisai to Divest Rights for Merislon and Myonal in Japan to ...

   www.jcnnewswire.com › english › pressrelease

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

4. www.acnnewswire.com › press-release › englishEisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, ...

   www.acnnewswire.com › press-release › english

   • 網頁紀錄

   2022年11月7日 · TOKYO, Nov 7, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a ...

5. www.webnewswire.com › 2024/03/30 › japan-eisai-to-divestJapan – Eisai to Divest Rights for Merislon and Myonal ...

   www.webnewswire.com › 2024/03/30 › japan-eisai-to-divest

   • 網頁紀錄

   2024年3月30日 · Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

6. www.asiaone.com › business › eisai-divest-rights-merislon-andEisai to Divest Rights for Merislon and Myonal in Japan to ...

   www.asiaone.com › business › eisai-divest-rights-merislon-and

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon®...

7. www.biospectrumasia.com › article › pdfEisai to divest rights for Merislon and Myonal in Japan to ...

   www.biospectrumasia.com › article › pdf

   2024年3月29日 · Eisai Co. has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken